| Date Filed | Type | Description |
| 05/02/2023 |
4
| Amado Rafael (Director) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 39,300 shares
@ $0
Granted 55,200 options to buy
@ $2.76, valued at
$152.4k
|
|
| 04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/05/2023 |
4
| Amado Rafael (See Remarks) has filed a Form 4 on Zai Lab Ltd|
Txns:
| Granted 113,217 options to buy
@ $33.95, valued at
$3.8M
Granted 21,564 options to buy
@ $0 |
|
| 01/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/11/2022 |
4
| Amado Rafael (EVP of R&D) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 19,120 shares
@ $0
Paid exercise price by delivering 8,464 shares
@ $11.8265, valued at
$100.1k
|
|
| 10/05/2022 |
4
| Amado Rafael (EVP of R&D) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 8,968 shares
@ $11.0617, valued at
$99.2k
|
|
| 08/02/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 2,000 shares
@ $11.97, valued at
$23.9k
|
|
| 07/06/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 2,000 shares
@ $11.44, valued at
$22.9k
|
|
| 06/22/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 2,000 shares
@ $11.18, valued at
$22.4k
|
|
| 05/19/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 11,500 shares
@ $7.3993, valued at
$85.1k
|
|
| 03/25/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 237,358 shares
@ $0
Granted 368,589 options to buy
@ $9.69, valued at
$3.6M
|
|
| 03/17/2022 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 5,169 shares
@ $7.709, valued at
$39.8k
|
|
| 10/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/30/2021 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 24,866 shares
@ $0
Granted 92,365 options to buy
@ $33.78, valued at
$3.1M
|
|
| 03/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/08/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2020 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 30,800 shares
@ $0
Granted 109,600 options to buy
@ $18.22, valued at
$2M
|
|
| 09/05/2019 |
4
| Amado Rafael (EVP of R&D and CMO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 105,162 shares
@ $0
Granted 160,630 options to buy
@ $26.15, valued at
$4.2M
|
|
| 09/05/2019 |
3
| Amado Rafael (EVP of R&D and CMO) has filed a Form 3 on Allogene Therapeutics, Inc. |
| 08/07/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/16/2019 |
4
| Amado Rafael (President, R & D) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Sold 3,028 shares
@ $5.3694, valued at
$16.3k
|
|
| 01/08/2019 |
4
| Amado Rafael (President, R & D) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 1,006,224 options to buy
@ $0
Granted 224,724 options to buy
@ $0 |
|
| 08/07/2018 |
4
| Amado Rafael (President, R & D) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 678,720 options to buy
@ $0 |
|
| 01/17/2018 |
4
| Amado Rafael (Chief Medical Officer) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 859,968 options to buy
@ $0
Granted 192,060 options to buy
@ $0 |
|
| 01/18/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |